GastroenterologyNews.net

Gastroenterology Xagena

Xagena Mappa
Medical Meeting
Gastrobase.it
Dermabase.it

Metastatic colon cancer: increased survival due to chemotherapy combined with surgical advances in liver resection


Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease.

Published in the Journal of Clinical Oncology, it is the first study in the last 20 years to examine the survival rates for metastatic colorectal cancer, and finds that the median overall survival is now more than 30 months, compared to eight months for patients diagnosed before 1990. Five-year survival of patients diagnosed with the disease after 2004 is more than 30 percent.

Colorectal cancer is the fourth most common cancer diagnosed in the United States. According to the American Cancer Society, in 2008, more than 148,800 people were diagnosed and 49,960 died from the disease.

Over the past decade, the concept that specific metastatic liver lesions can be surgically removed has become more widely accepted as practice. Thus, more emphasis is now placed on identifying candidates for resection of their liver metastasis.

In the study, Researchers wanted to determine if these changes resulted in longer survival of metastatic colorectal cancer patients in a large population base.
A second goal of the study was to determine which of the two modalities, surgery or chemotherapy, was responsible for the change in outcome, and when did the modalities have the most impact,

For the retrospective, population-based study, the Researchers identified 2,470 newly diagnosed metastatic colorectal cancer patients at two institutions – MD Anderson ( 1,614 patients ) and Mayo Clinic ( 856 patients ), treated between 1990 and 2006. All patients received at least a portion of their therapy at one of the two institutions.

Of the 2,470 patients, 231 underwent hepatic resection, with the surgical procedure being preformed with increased frequency after 2000.

To determine the changes in outcome, the Researchers looked to see if patients were able to undergo resection for their liver metastasis and when surgery outcome took place, as well as changes in chemotherapy utilization at the institutions over time.

The Researchers found no significant change in overall survival in patients diagnosed 1990- 1997; the median for that date range was 14.2 months. However, during the time periods 1998-2000, 2001-2003 and 2004-2006, the median overall survival rates increased from 18 months, to 18.6 months, to 29.2 months respectively. Five-year overall survival also increased over time: from 9.1 percent ( diagnosed 1990-1997 ); to 13 percent ( diagnosed 1998-2000 ); to 19.2 percent ( diagnosed 2001-2003 ). Five-year survival for patients diagnosed 2004-2006 has not yet been determined but is projected to increase to more than 30 percent.

To confirm their findings, Researchers used the National Cancer Institute's Surveillance, Epidemiology and End Results ( SEER ), the population-based cancer registry, to identify 49,459 patients diagnosed with metastatic colon cancer between 1990 and 2005. The data showed early evidence of similar improvements in five-year and median overall survival in more recent years.

In the study, Researchers compared their findings to the incremental leaps of breast cancer survivorship of about a decade ago, when the development of new chemotherapy and hormonal agents revolutionized that disease.
Looking at when these changes in colon cancer survivorship occurred, the study showed two distinct time periods that reflect the impact of both hepatic resections and the availability of new novel therapies.
Beginning in 1998 and even more by 2000, Researchers started performing higher volumes of hepatic resections, and that coincided with the initial increase in survival. The second stage of improvement began around 2004, simultaneous to the approval of many more chemotherapy and biological agents ( Cetuximab, Bevacizimab, Oxaliplatin.

Source: University of Texas MD Anderson Cancer Center, 2009

XagenaMedicine_2009



Indietro